These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9615715)

  • 1. Roscovitine inhibits the proliferative activity of immortal and neoplastic human breast epithelial cells.
    Mgbonyebi OP; Russo J; Russo IH
    Anticancer Res; 1998; 18(2A):751-5. PubMed ID: 9615715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells.
    Mgbonyebi OP; Russo J; Russo IH
    Cancer Res; 1999 Apr; 59(8):1903-10. PubMed ID: 10213499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Mar; 112(3):761-72. PubMed ID: 21328450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
    Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
    Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells.
    Mgbonyebi OP; Russo J; Russo IH
    Int J Oncol; 1998 Apr; 12(4):865-9. PubMed ID: 9499448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
    Mihara M; Shintani S; Kiyota A; Matsumura T; Wong DT
    Int J Oncol; 2002 Jul; 21(1):95-101. PubMed ID: 12063555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
    David-Pfeuty T
    Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells.
    Wu PC; Tai MH; Hu DN; Lai CH; Chen YH; Wu YC; Tsai CL; Shin SJ; Kuo HK
    J Ocul Pharmacol Ther; 2008 Feb; 24(1):25-33. PubMed ID: 18370874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference with ER-α enhances the therapeutic efficacy of the selective CDK inhibitor roscovitine towards ER-positive breast cancer cells.
    Węsierska-Gądek J; Gritsch D; Zulehner N; Komina O; Maurer M
    J Cell Biochem; 2011 Apr; 112(4):1103-17. PubMed ID: 21308739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roscovitine differentially affects asynchronously growing and synchronized human MCF-7 breast cancer cells.
    Maurer M; Komina O; Wesierska-Gadek J
    Ann N Y Acad Sci; 2009 Aug; 1171():250-6. PubMed ID: 19723062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
    Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
    Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5.
    Goodyear S; Sharma MC
    Exp Mol Pathol; 2007 Feb; 82(1):25-32. PubMed ID: 17081516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells.
    Yin F; Giuliano AE; Law RE; Van Herle AJ
    Anticancer Res; 2001; 21(1A):413-20. PubMed ID: 11299771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anti-estrogen combined with roscovitine, a selective CDK inhibitor, on human breast cancer cells differing in expression of ER.
    Zulehner N; Maurer M; Wesierska-Gadek J
    J Exp Ther Oncol; 2011; 9(1):17-25. PubMed ID: 21275262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines.
    Brandi G; Paiardini M; Cervasi B; Fiorucci C; Filippone P; De Marco C; Zaffaroni N; Magnani M
    Cancer Res; 2003 Jul; 63(14):4028-36. PubMed ID: 12874002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
    N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
    Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells.
    Damiens E; El Yazidi I; Mazurier J; Duthille I; Spik G; Boilly-Marer Y
    J Cell Biochem; 1999 Sep; 74(3):486-98. PubMed ID: 10412049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine).
    McClue SJ; Blake D; Clarke R; Cowan A; Cummings L; Fischer PM; MacKenzie M; Melville J; Stewart K; Wang S; Zhelev N; Zheleva D; Lane DP
    Int J Cancer; 2002 Dec; 102(5):463-8. PubMed ID: 12432547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
    Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
    Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.